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Drug biotransformation studies appear as an alternative to pharmacological investigations of metabolites, development of 
new drug candidates with reduced investment and most efficient production. The objective of this study was to evaluate 
the capacity of biotransformation of Rifampicin (RIF) by the filamentous fungus Cunninghamella elegans as a microbial 
model of mammalian metabolism. In 120 h, C. elegans transformed the drug into the following two metabolites: rifampicin 
quinone and novel metabolite. The products of rifampicin formed in vitro were monitored by HPLC-PDA, being identified 
through UHPLC–QTOF/MS. Metabolites were characterized according to their chromatographic profile, mass fragments 
and UV spectral data. The major metabolic pathways of rifampicin transformed by the fungus were oxidation, 
demethylation and mono-oxidation. The microbial transformation of RIF showed the potential of Cunninghamella species 
to produce RIF metabolites. This process can be used for a cost effective method for both known and unknown metabolite 
production. 
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Introduction 
 
Rifampicin (RIF), a semisynthetic macrocyclic 
antibiotic, is widely used in the treatment of tuberculosis 
and staphylococcal infection. RIF acts by binding to the 
bacterial RNA (ribonucleic acid) polymerase which 
consequently blocks the synthesis of the bacterial RNA 
messenger (1). This drug has peculiar pharmacokinetic 
properties. RIF is well absorbed orally being widely 
distributed in body tissues and fluids. Its metabolism in 
humans occurs in the liver by the cytochrome (CYP) 
P450 resulting in the active metabolite 25-
desacetylrifampicin among other molecules (2,3,4).  
Microbial transformation has been used as a simple 
methodology for in vitro drug metabolism studies (5). 
Biotransformation using microorganisms offers the 
opportunity to help elucidating biosynthetic pathways, 
anticipate mammalian metabolism, and toxicity (6). 
Additionally, biotransformation reaction technology is 
considered to be an alternative for the development of 
sustainable technologies for the production of chemicals 
and drugs using principles of green chemistry (7).  
Biotransformation products can be labelled as ‘natural’ 
according to US and European (8).  
Cunninghamella, a filamentous fungus, is considered 
one of the most important microorganisms for 
biotransformation studies since it can catalyze several 
reactions to various classes of compounds. Studies have 
demonstrated the ability of this fungus to metabolize a 
wide variety of drugs by mechanisms which are similar 
to what is observed during Phase I and II metabolism of 
mammals (9-12). Cunninghamella elegans carries at 
least one gene coding for a CYP enzyme closely related 
to the CYP51 family. These enzymes produce 
metabolites in amounts which allow the isolation of the 
same compounds generated by humans and animal 
metabolism. Besides, novel C. elegans metabolites 
presenting pharmacological interest also can be isolated 
(13,14). 
The aim of the present work was to evaluate the 
formation of metabolites of rifampicin using filamentous 
fungi Cunninghamella elegans ATCC 9245 through the 
use of robust analytical techniques with the ultra-high 
performance liquid chromatography-quadrupole time-
of-flight mass spectrometry (UHPLC–QTOF/MS) for 
analysis and prediction of the chemical structure of the 
metabolites in the sample. 
 
Material and methods 
Chemicals and reagents 
RIF (purity  95%) was donated by Professor Myraci 
Muniz de Albulquerque (Pernambuco Federal 
University, Brazil). Rifampicin quinone (purity  
99.99%) United States Pharmacopeia (USP) reference 
standard was purchased from USP.  Dichloromethane 
was purchased from Dinâmica (Diadema, Brazil) and 
N,N-dimethylformamide from Labsynth (Diadema, São 
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Paulo). Methanol, acetonitrile, and ethanol of HPLC 
grade were purchased from Merck (New Jersey, USA), 
Vetec (São Paulo, Brazil), and Panreac (Barcelona, 
Spanish), respectively. Czapek-Dox broth and sabouraud 
dextrose agar were obtained from Kasvi (Paraná, Brazil). 
Water was purified by a Milli-Q system Millipore 
(Molsheim, France).  
 
 
Microbial Culture and Biotransformation Conditions 
 
Cunninghamella elegans ATCC 9245 was donated by 
the Bioconversion laboratory, Goiás Federal Univesity, 
Goiânia, Brazil. Stock cultures were cut in discs of 0.5 
cm of diameter and maintained on sterile sodium 
chloride 0.9% (w/v) at 5 C.   
Spore solutions of C. elegans were prepared by growing 
the fungi for 7 days at 28 ºC in tubes containing a 
sabouraud dextrose agar. Czapek-Dox liquid medium 
diluted to 50% (Sodium nitate 1.0 g/L, Magnesium 
Sulphate 0.25 g/L, Potassium Chloride 0.25 g/L, Di 
Potassium Phosphate 0.5 g/L, Ferrous Sulfate 0.005 g/L, 
and Sucrose 15 g/L, pH 7.0), 100 ml of this was measured 
with 1016 spores mL-1 of strain inoculated for 3 days at 
28 C in an orbital shaker (New Brunswick™ 
Innova® 2300) at 120 rpm. Then, the substrate (250 mg), 
which was previously solved in N,N-
dimethylformamide:ethanol (1:1 v/v) was added into 
each flask to give the final RIF concentration of 500 
µg/mL. The cultures were incubated at 28 C, shaking at 
120 rpm, for 120 h. Samples (2 mL) of the liquid culture 
were periodically (1, 3, 4 and 5 days) withdrawn from 
each culture and extracted three times successively with 
dichloromethane (4 mL). Each extract was separately 
evaporated to dryness in exhaust hood at room 
temperature. The residues obtained were dissolved in 2 
mL acetonitrile:water (1:1), filtered and 25 μL (injection 
volume) analyzed by liquid chromatography. Control 
flasks consisted of culture broth without RIF (positive 
control: C+), only sterile medium with RIF (negative 
control: C-), and culture broth (blank: W). Control flasks 
were included in the HPLC analysis. 
 
Instrumentation and HPLC conditions 
For characterization of metabolites, an HPLC method 
was first developed and validated (data nor shown) 
followed international guidelines (15). Liquid 
chromatographic analyses were conducted on a 
Shimadzu LC-10A system (Kyoto, Japan) equipped with 
an LC-20AT pump, SPD-20AV UV-VIS variable 
wavelength detector, DGU-20A5 degasser, CBM-20A 
controller system, and SIL-20A injection valve with 100 
μL loop. Phenomenex C18 column (5 μm, 250 mm x 4.6 
mm i.d.) and C8 guard column (4 x 3.0 mm; 
Phenomenex, USA) were kept at 30 °C using a mobile 
phase consisting of a mixture of ammonium acetate 
0.01M, pH 4.0 and acetonitrile (50:50, v/v) at a flow rate 
of 1.0 mL min-1 with UV detection at 254 nm. 
 
Identification of metabolites: LC-QTOF MS analysis 
 
The structural elucidation of the metabolites formed was 
performed through the UHPLC-QTOF/MS system, 
UHPLC (Shimadzu-Nexera x2) equipped with a Shin-
pack XR ODS III column (2.0 mm × 50 mm, 1.6 μm) 
from Shimadzu coupled to the QTOF-MS mass analyzer 
(Impact II, Bruker Daltonics). The QTOF-MS system 
was equipped with an electrospray ionization (ESI) 
source, operating in positive ionization mode. The 
mobile phase consisted of acetonitrile and ammonium 
acetate 0,01M pH 4.0. The operation parameters of ESI 
were the following: capillary voltage, 4000 V; end plate 
offset, 500 V; nebulizer pressure, 4 bar (N2); drying gas, 
0.28 L/min (N2); and drying temperature, 200 °C. The 
QTOF-MS system was operating in broadband collision-
induced dissociation (bbCID) acquisition mode and 
recorded spectra over the range m/z 50−1000 with a scan 
rate of 2 Hz. A QTOF-MS external calibration was 
performed before each injection with a sodium formate 
solution. Data treatments were processed with Data 
Analysis 4.2 Software.  
After 120 h of experiment, aliquots of biotransformation 
medium (drug, fungus, and medium: BIO), C-, C+, and 
W were collected, extracted, and analyzed by UHPLC-
QTOF/MS. 
 
Results and Discussion 
 
Few information regarding the chromatographic analysis 
of RIF metabolites in vivo and in vitro are known. Passad 
and Singh (2009) studied the biotransformation of 
rifampicin in vitro (rat liver S9 fraction and microsomes) 
and in vivo (Sprague–Dawley rats). A total of 21 
metabolites were identified, among them3-
formylrifamycin, rifampicin quinone and 
desacetylrifampicin (17,18).  
A representative HPLC–PDA chromatogram of 
rifampicin and its metabolites after 120 hours of 
transformation by C. elegans is shown in Fig. 1, which 
demonstrated the data from the biotransformation study, 
with the chromatogram (A) corresponding to the 
biotransformation medium (medium, fungus and drug), 
(B) negative control (medium and drug) (C) standard of 
the RIF quinone. The substrate controls showed there 
were no interference signals with the formed metabolites 
and the drug. The results of HPLC–PDA analyses 
indicated that RIF was metabolized in the 
biotransformation medium. It is possible to observe the 
RIF standard in 5.0 min, and RIF quinone in 9.5 min 
(Figure 1, peak 2), which was confirmed by injection RIF 
quinone standard plus Czapek-Dox medium. 
Furthermore, in biotransformation medium (Fig 1A) 
another two peaks were detected, which can be related to 
possible metabolites (Fig 1; peaks 1 and 3).  
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Figure 1: Chromatographic profile (HPLC-DAD) of reactional 
medium after 120h. (A) biotransformation medium (medium, 
drug and fungi), (B) negative control (medium and drug) and 
(C) standard RIF quinone. (1) and (3): possible metabolites. (2): 
RIF quinone. 
After 120h of incubation, being collected on day 1, 4 and 
5 after adding the drug, it is possible to observe the 
reduction (66.6%) of the drug concentration in relation to 
the negative control, which was submitted to the same 
extraction process. This behavior suggests drug 
consumption due to the action of the fungus and not only 
a process of drug oxidation caused by the culture 
medium. In this case, the fungus acts as a catalyst, 
accelerating the metabolization/degradation of RIF 
(Figure 2).  
 
 
 
Figure 2: Decay representative graph of RIF concentration in 
5 days of biotransformation, compared to the negative control 
in the same conditions. BIO (biotransformation medium); C- 
(negative control). 
  
The modern analytical techniques, in special hyphenated 
systems like UHPLC-QTOF/MS, are very useful to 
identify the biotransformation products even without 
previous treatment for separation of individual 
metabolites. Here in the present work, the samples were 
analyzed through UHPLC-QTOF/MS for elucidation of 
probable metabolites formed. The analytical conditions 
used were similar to the HPLC-DAD method and 
demonstrated good results. Analyzing the 
biotransformation medium (BIO) by UHPLC-QTOF/MS 
it is possible to detect the derivative rifampicin quinone 
(m/z 821.3962). Mass studies revealed the difference of 
two hydrogens (2.0157) in the structure, as compared to 
the drug standard. As illustrated on Figure 3, this 
metabolite is also detected in the negative control 
sample, but in a small intensity as compared to 
biotransformation medium (Fig 3A). As shown in Figure 
3(B), mass fragmentation of RIF quinone resulted two 
stable fragments of m/z 789.3694 (N-demethylation) and 
436.2324 (loss of aromatic and piperazine rings) (Figure 
4). Other peaks were detected on zooming the spectra. 
 
 
Figure 3: Comparative chromatograms of biotransformation 
medium (BIO) and negative control (A) and MS spectra of 
proposed metabolite, rifampicin quinone, in ESI mode positive 
(B). 
Literature reports that the metabolite RIF quinone is 
formed in aqueous solutions favored by neutral and basic 
conditions, as well as naturally by oxidation (16). Then, 
RIF quinone is suggested as a degradation product whose 
formation is stimulated in the biotransformation medium, 
thus suggesting that the fungus used in this study 
accelerated the formation of the degradation product 
(16,19,20). The degradation of an antibiotic favored by a 
filamentous fungus, which is found in the environment, 
is a positive point when the subject is bioremediation.  
 
Figure 4: Proposed structures of RIF quinone and mass 
fragments obtained from UHPLC-QTOF/MS in ESI positive 
ion mode, after 120 hours of the biotransformation. 
 
RIF can be metabolized either by hydrolysis to 
formylrifampicin or by deacetylation to form desacetyl 
rifampicin which retains practically all antibacterial 
activity. It was not possible to identify these known 
metabolites in the biotransformation medium, it was not 
possible to identify these metabolites already listed in the 
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literature in the biotransformation medium, it is believed 
that by making some changes such as culture medium, 
agitation, concentration of the substrate (drug), inoculum 
or use of another microorganism, it could be detected in 
the study (21,22).   
Observing the chromatogram illustrated in the Figure 5 
after 5 days’ biotransformation study obtained from 
UHPLC-QTOF/MS analysis, the metabolite eluted at 
retention time of 10.0 min (Figure 5A) refers possibly to 
the peak detected in 11.5 min in HPLC-DAD analysis 
(Figure 1 peak 3). This product was found only in the 
biotransformation medium with C. elegans. The mass 
spectrum (Figure 5B) of this metabolite showed a 
molecular ion at m/z 452.3217 (Figure 5), with a loss of 
370.6622 in reference to the molecular weight of 
rifampicin.  
 
 
 
Figure 5: UHPLC-QTOF/MS chromatogram obtained from 
analysis of biotransformation medium in the study of 
rifampicin using Cunninghamella elegans. Chromatograms of 
overlapping biotransformation medium and negative control 
for comparison of the detected peaks (A), and mass spectrum 
of proposed metabolite (m/z 452.3217) (B).  
 
The proposed molecular formula for this metabolite is 
C25H40O7 indicating the loss of eighteen carbons, five 
oxygen atoms and four nitrogens. It is suggested that the 
formation of this metabolite through ring cleavage, 
demethylation and loss of the piperazine fraction, which 
can be characterized as a RIF monoxygenation product 
(m/z 451.1974) (Figure 6). For elucidation, our results 
were evaluated considering the study from Prasad and 
Singh (2009), which purposes a biotransformation 
pathway for rifampicin. Mono-oxygenation is mentioned 
as a way for metabolism and probably is involved to 
increase the drug polarity. In our case, the acetyl group 
is maintained intact, even being an important metabolic 
route, as reported by Prasad and Singh (2009). These 
authors have mentioned three metabolites formed by 
desacetylation: desacetylrifampicin, desacetyl-3-
formylrifampicin, and N-demethyl-desacetylrifampicin. 
From our mass spectra results and possibilities for 
fragmentation, we have indicated a possible loss of 
hydroxyl group (m/z 434.1941) and desacetylation with 
other few modifications (m/z 317.1954) (Figure 6). This 
mono-oxygenated RIF metabolite with this purposed 
chemical structure is a novel compound, being described 
for the first time in the literature, even though Prasad and 
Singh (2009) report mono-oxygenation for RIF 
metabolism.  
 
Figure 6: Proposed chemical structure of RIF metabolite (m/z 
452.3217) obtained from biotransformation study with C. 
elegans ATCC 9245. 
Conclusions 
In the present study, the microbial transformation of an 
important antibiotic with C. elegans was investigated. 
The results showed that rifampicin antibiotics were 
biotransfomed by fungi Cunninghamella elegans ATCC 
9245 transforming a compound known as rifampicin 
quinone and generating another metabolite not yet 
reported in the literature. The structural elucidation of all 
metabolites were done based on mass fragmentation 
study combined with accurate mass measurements. In 
this study we observed great ability of C. elegans to 
metabolize rifampicin demonstrating that this microbial 
system represents an attractive alternative to the use of 
mammalian systems or chemical synthesis. 
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